Literature DB >> 33444944

The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study.

Rose Fluss1, Andrew J Kobets2, Julio F Inocencio1, Mousa Hamad1, Chaim Feigen1, David J Altschul1, Patrick Lasala1.   

Abstract

INTRODUCTION: Historically, the development of venous thromboembolism (VTE) including deep venous thrombosis (DVT) and pulmonary thromboembolism (PE) was cited as a higher post-operative risk for patients harboring meningiomas. However, recent literature has suggested that there may be no elevated risk for VTE among these patients. The authors perform both a retrospective review of their own cases as well as a systematic review of the literature in order to determine the frequency of the VTE and rate of post-operative hemorrhage in this patient population.
METHODOLOGY: Patients undergoing surgery for intracranial and spinal meningioma from 2012 to 2019 were retrospectively reviewed for patient demographics, clinical characteristics, and post-operative complications. Logistic regression was used to determine risk factors for the development of VTE. Additionally, a PubMed search was performed to identify patients addressing this topic.
RESULTS: Our retrospective review included 189 patients who underwent 197 operations. The rate of VTE for patients receiving LMWH was 3.55 % vs. 4.06 % for those not receiving LMWH. There were no observed hemorrhages after initiation of LMWH. Multivariate analysis found tumor volume, history of DVT, and length of hospital stay as independent risk factors for VTE. In the systematic review, 11 papers describing 28,954 patients were included. The risk of developing a VTE with or without LMWH was 2.71 % versus 4.07 %, respectively. The hemorrhage risk was 2.23 % on LMWH versus 4.20 % not on LMWH. DISCUSSION: In several heterogeneous series of all types of neurosurgical procedures, the reported rate of VTE was 11.1 %. In our review of the literature, the VTE rate of 2.71 % was similar to our cohort's rate of 3.55 %, for patients administered LMWH postoperatively. Higher rates of VTE with meningiomas may not be the case as once thought. Regular use of LMWH appears to be a safe, but it also did not necessarily lower the rates of VTE in our cohort. The use of routine lower-extremity duplex ultrasound, mechanical prophylaxis, and early mobilization, may have contributed to these lower rates of VTEs in patients with meningiomas.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Deep vein thrombosis; Low-molecular-weight-heparin; Lower-extremity duplex ultrasound; Meningioma; Pulmonary embolism; Venous thromboembolism

Year:  2021        PMID: 33444944     DOI: 10.1016/j.clineuro.2020.106460

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

1.  Systemic coagulation is activated in patients with meningioma and glioblastoma.

Authors:  Swaroopa Yerrabothala; Brett L Gourley; James C Ford; Syed Rakin Ahmed; Stephen J Guerin; Marc Porter; Heather A Wishart; Marc S Ernstoff; Camilo E Fadul; Deborah L Ornstein
Journal:  J Neurooncol       Date:  2021-10-15       Impact factor: 4.130

2.  Critical appraisal of minimally invasive keyhole surgery for intracranial meningioma in a large case series.

Authors:  Jai Deep Thakur; Regin Jay Mallari; Alex Corlin; Samantha Yawitz; Amalia Eisenberg; John Rhee; Walavan Sivakumar; Howard Krauss; Neil Martin; Chester Griffiths; Garni Barkhoudarian; Daniel F Kelly
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

3.  Venous thromboembolic events in glioblastoma patients: An epidemiological study.

Authors:  Amanda Eisele; Katharina Seystahl; Elisabeth J Rushing; Patrick Roth; Emilie Le Rhun; Michael Weller; Dorothee Gramatzki
Journal:  Eur J Neurol       Date:  2022-05-31       Impact factor: 6.288

4.  Streamlining brain tumor surgery care during the COVID-19 pandemic: A case-control study.

Authors:  Regin Jay Mallari; Michael B Avery; Alex Corlin; Amalia Eisenberg; Terese C Hammond; Neil A Martin; Garni Barkhoudarian; Daniel F Kelly
Journal:  PLoS One       Date:  2021-07-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.